CN107739759A - 一种rdh10基因在脑胶质瘤疾病中的应用 - Google Patents
一种rdh10基因在脑胶质瘤疾病中的应用 Download PDFInfo
- Publication number
- CN107739759A CN107739759A CN201710837818.2A CN201710837818A CN107739759A CN 107739759 A CN107739759 A CN 107739759A CN 201710837818 A CN201710837818 A CN 201710837818A CN 107739759 A CN107739759 A CN 107739759A
- Authority
- CN
- China
- Prior art keywords
- rdh10
- glioma
- cell
- genes
- shrna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 17
- 201000007983 brain glioma Diseases 0.000 title claims abstract description 12
- 101001111656 Homo sapiens Retinol dehydrogenase 10 Proteins 0.000 title claims abstract 20
- 206010018338 Glioma Diseases 0.000 claims abstract description 89
- 208000032612 Glial tumor Diseases 0.000 claims abstract description 76
- 239000004055 small Interfering RNA Substances 0.000 claims abstract description 65
- 230000014509 gene expression Effects 0.000 claims abstract description 63
- 101150035427 RDH10 gene Proteins 0.000 claims abstract description 18
- 230000006907 apoptotic process Effects 0.000 claims abstract description 17
- 108091027967 Small hairpin RNA Proteins 0.000 claims abstract description 14
- 230000012010 growth Effects 0.000 claims abstract description 13
- 230000009545 invasion Effects 0.000 claims abstract description 8
- 238000003209 gene knockout Methods 0.000 claims abstract description 7
- 238000000338 in vitro Methods 0.000 claims abstract description 7
- 238000001727 in vivo Methods 0.000 claims abstract description 7
- 230000006698 induction Effects 0.000 claims abstract description 7
- 241000699660 Mus musculus Species 0.000 claims abstract description 6
- 230000001404 mediated effect Effects 0.000 claims abstract description 6
- 238000011580 nude mouse model Methods 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 33
- 241000700605 Viruses Species 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 10
- 230000004709 cell invasion Effects 0.000 claims description 4
- 230000004668 G2/M phase Effects 0.000 claims description 3
- 230000006369 cell cycle progression Effects 0.000 claims description 3
- 238000010276 construction Methods 0.000 claims description 2
- 102100023918 Retinol dehydrogenase 10 Human genes 0.000 claims 3
- 230000007423 decrease Effects 0.000 claims 1
- 230000004083 survival effect Effects 0.000 abstract description 11
- 230000022131 cell cycle Effects 0.000 abstract description 7
- 241000713666 Lentivirus Species 0.000 abstract description 4
- 238000002626 targeted therapy Methods 0.000 abstract description 3
- 108050002017 Retinol dehydrogenase 10 Proteins 0.000 description 109
- 102000012464 Retinol dehydrogenase 10 Human genes 0.000 description 95
- 210000004027 cell Anatomy 0.000 description 87
- 206010028980 Neoplasm Diseases 0.000 description 28
- 238000004458 analytical method Methods 0.000 description 24
- 208000005017 glioblastoma Diseases 0.000 description 18
- 201000011510 cancer Diseases 0.000 description 12
- 102100024584 Tumor necrosis factor ligand superfamily member 12 Human genes 0.000 description 10
- 238000002493 microarray Methods 0.000 description 10
- 230000033228 biological regulation Effects 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 101710097155 Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 description 8
- 238000004393 prognosis Methods 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- KXTYBXCEQOANSX-UHFFFAOYSA-N Fusicoccin A Natural products C12=C(C(C)COC(C)=O)CC(O)C2(C)C=C2C(COC)CCC2C(C)C(O)C1OC1OC(COC(C)(C)C=C)C(O)C(OC(C)=O)C1O KXTYBXCEQOANSX-UHFFFAOYSA-N 0.000 description 7
- 102100039337 NF-kappa-B inhibitor alpha Human genes 0.000 description 7
- 238000011529 RT qPCR Methods 0.000 description 7
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 7
- 229930188044 fusicoccin Natural products 0.000 description 7
- KXTYBXCEQOANSX-MQYZIMMHSA-N fusicoccin Chemical compound O([C@@H]1[C@@H](O)[C@H](C)[C@H]\2CC[C@H](C/2=C/[C@@]2(C)[C@H](O)CC(=C21)[C@H](C)COC(C)=O)COC)[C@H]1O[C@@H](COC(C)(C)C=C)[C@H](O)[C@@H](OC(C)=O)[C@@H]1O KXTYBXCEQOANSX-MQYZIMMHSA-N 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 101000961071 Homo sapiens NF-kappa-B inhibitor alpha Proteins 0.000 description 5
- 239000012190 activator Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000004043 dyeing Methods 0.000 description 5
- 238000010208 microarray analysis Methods 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 229930002330 retinoic acid Natural products 0.000 description 5
- 230000003827 upregulation Effects 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 description 4
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 4
- 241001269238 Data Species 0.000 description 4
- 102100031150 Growth arrest and DNA damage-inducible protein GADD45 alpha Human genes 0.000 description 4
- 101001066158 Homo sapiens Growth arrest and DNA damage-inducible protein GADD45 alpha Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000001994 activation Methods 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000000412 Annexin Human genes 0.000 description 3
- 108050008874 Annexin Proteins 0.000 description 3
- 102100025422 Bone morphogenetic protein receptor type-2 Human genes 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 101000934635 Homo sapiens Bone morphogenetic protein receptor type-2 Proteins 0.000 description 3
- 102000001284 I-kappa-B kinase Human genes 0.000 description 3
- 108060006678 I-kappa-B kinase Proteins 0.000 description 3
- 238000003559 RNA-seq method Methods 0.000 description 3
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 description 3
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000009456 molecular mechanism Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 101100243447 Arabidopsis thaliana PER53 gene Proteins 0.000 description 2
- 108700003785 Baculoviral IAP Repeat-Containing 3 Proteins 0.000 description 2
- 102100021662 Baculoviral IAP repeat-containing protein 3 Human genes 0.000 description 2
- 101150104237 Birc3 gene Proteins 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 101001005550 Homo sapiens Mitogen-activated protein kinase kinase kinase 14 Proteins 0.000 description 2
- 101000998194 Homo sapiens NF-kappa-B inhibitor epsilon Proteins 0.000 description 2
- 101000830598 Homo sapiens Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 description 2
- 102100025211 Mitogen-activated protein kinase kinase kinase 14 Human genes 0.000 description 2
- 101100140239 Mus musculus Rdh10 gene Proteins 0.000 description 2
- 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 2
- 102100033104 NF-kappa-B inhibitor epsilon Human genes 0.000 description 2
- 102000019148 NF-kappaB-inducing kinase activity proteins Human genes 0.000 description 2
- 108040008091 NF-kappaB-inducing kinase activity proteins Proteins 0.000 description 2
- 108700019961 Neoplasm Genes Proteins 0.000 description 2
- 102000048850 Neoplasm Genes Human genes 0.000 description 2
- 101100379220 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) API2 gene Proteins 0.000 description 2
- 102000004398 TNF receptor-associated factor 1 Human genes 0.000 description 2
- 108090000920 TNF receptor-associated factor 1 Proteins 0.000 description 2
- 101150080074 TP53 gene Proteins 0.000 description 2
- 102000007150 Tumor Necrosis Factor alpha-Induced Protein 3 Human genes 0.000 description 2
- 108010047933 Tumor Necrosis Factor alpha-Induced Protein 3 Proteins 0.000 description 2
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 2
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 2
- 206010064390 Tumour invasion Diseases 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000009400 cancer invasion Effects 0.000 description 2
- 230000025084 cell cycle arrest Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 102100023932 Bcl-2-like protein 2 Human genes 0.000 description 1
- 101150008012 Bcl2l1 gene Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100021246 DDIT3 upstream open reading frame protein Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 230000035519 G0 Phase Effects 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 102100031153 Growth arrest and DNA damage-inducible protein GADD45 beta Human genes 0.000 description 1
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 1
- 101000904691 Homo sapiens Bcl-2-like protein 2 Proteins 0.000 description 1
- 101001066164 Homo sapiens Growth arrest and DNA damage-inducible protein GADD45 beta Proteins 0.000 description 1
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 1
- 101000990912 Homo sapiens Matrilysin Proteins 0.000 description 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 1
- 101000775102 Homo sapiens Transcriptional coactivator YAP1 Proteins 0.000 description 1
- 102100030417 Matrilysin Human genes 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100046559 Mus musculus Tnfrsf12a gene Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 101710142587 Short-chain dehydrogenase/reductase Proteins 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 108010057666 Transcription Factor CHOP Proteins 0.000 description 1
- 102100031873 Transcriptional coactivator YAP1 Human genes 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 102000055104 bcl-X Human genes 0.000 description 1
- 108700000711 bcl-X Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000003208 gene overexpression Methods 0.000 description 1
- 210000002165 glioblast Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000010376 human cloning Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 208000030173 low grade glioma Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000003012 network analysis Methods 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- -1 propidium iodides Chemical class 0.000 description 1
- 108010062302 rac1 GTP Binding Protein Proteins 0.000 description 1
- 102000010838 rac1 GTP Binding Protein Human genes 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010043688 thyroid adenoma Diseases 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710837818.2A CN107739759B (zh) | 2017-09-18 | 2017-09-18 | 一种rdh10基因在脑胶质瘤疾病中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710837818.2A CN107739759B (zh) | 2017-09-18 | 2017-09-18 | 一种rdh10基因在脑胶质瘤疾病中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107739759A true CN107739759A (zh) | 2018-02-27 |
CN107739759B CN107739759B (zh) | 2021-02-19 |
Family
ID=61235749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710837818.2A Active CN107739759B (zh) | 2017-09-18 | 2017-09-18 | 一种rdh10基因在脑胶质瘤疾病中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107739759B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110241210A (zh) * | 2019-06-11 | 2019-09-17 | 复旦大学 | Rit1基因作为治疗脑胶质瘤药物干预靶点的应用 |
CN114452378A (zh) * | 2022-01-20 | 2022-05-10 | 中山大学 | Rdh10和/或其前药在制备治疗和/或预防糖尿病心肌损伤的药物中的应用 |
CN114451357A (zh) * | 2022-01-20 | 2022-05-10 | 中山大学 | 一种基于心肌视黄醇代谢紊乱的成年小鼠心衰模型的构建方法 |
-
2017
- 2017-09-18 CN CN201710837818.2A patent/CN107739759B/zh active Active
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110241210A (zh) * | 2019-06-11 | 2019-09-17 | 复旦大学 | Rit1基因作为治疗脑胶质瘤药物干预靶点的应用 |
CN110241210B (zh) * | 2019-06-11 | 2023-02-10 | 复旦大学 | Rit1基因作为治疗脑胶质瘤药物干预靶点的应用 |
CN114452378A (zh) * | 2022-01-20 | 2022-05-10 | 中山大学 | Rdh10和/或其前药在制备治疗和/或预防糖尿病心肌损伤的药物中的应用 |
CN114451357A (zh) * | 2022-01-20 | 2022-05-10 | 中山大学 | 一种基于心肌视黄醇代谢紊乱的成年小鼠心衰模型的构建方法 |
Also Published As
Publication number | Publication date |
---|---|
CN107739759B (zh) | 2021-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pertega‐Gomes et al. | A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy | |
Gao et al. | Down-regulation of CXCL11 inhibits colorectal cancer cell growth and epithelial-mesenchymal transition | |
Tang et al. | Opposite effects of interferon regulatory factor 1 and osteopontin on the apoptosis of epithelial cells induced by TNF-α in inflammatory bowel disease | |
Hu et al. | MicroRNA‐329‐mediated PTTG1 downregulation inactivates the MAPK signaling pathway to suppress cell proliferation and tumor growth in cholangiocarcinoma | |
Xu et al. | Activated iRhom2 drives prolonged PM2. 5 exposure-triggered renal injury in Nrf2-defective mice | |
CN110129447A (zh) | Pqbp1在卵巢癌诊治中的应用 | |
CN107739759A (zh) | 一种rdh10基因在脑胶质瘤疾病中的应用 | |
Xie et al. | Knockdown of TRIM26 inhibits the proliferation, migration and invasion of bladder cancer cells through the Akt/GSK3β/β-catenin pathway | |
Zhang et al. | Thymidine phosphorylase promotes metastasis and serves as a marker of poor prognosis in hepatocellular carcinoma | |
Ouyang et al. | RETRACTED ARTICLE: SIRT6 overexpression induces apoptosis of nasopharyngeal carcinoma by inhibiting NF-κB signaling | |
Li et al. | LncRNA STARD13-AS blocks lung squamous carcinoma cells growth and movement by targeting miR-1248/C3A | |
Zhang et al. | Lipopolysaccharide‐induced proliferation and glycolysis in airway smooth muscle cells via activation of Drp1 | |
Huang et al. | Rab1A promotes IL-4R/JAK1/STAT6-dependent metastasis and determines JAK1 inhibitor sensitivity in non-small cell lung cancer | |
CN108273062A (zh) | Foxm1抑制剂在肝内胆管细胞癌治疗中的作用 | |
Xu et al. | lncRNA Gm16410 mediates PM2. 5-induced macrophage activation via PI3K/AKT pathway | |
CN107739758A (zh) | 一种RDH10基因用于制备TWEAK‑NF‑κB信号通路阻断剂的应用 | |
Wang et al. | Silencing of PRDM5 increases cell proliferation and inhibits cell apoptosis in glioma | |
Wu et al. | G protein-coupled receptor kinase 2 regulating β2-adrenergic receptor signaling in M2-polarized macrophages contributes to hepatocellular carcinoma progression | |
Wu et al. | High-expression of lncRNA CEBPA-AS1 promotes liver cancer progression. | |
Liu et al. | Mitofusin1 is a major mediator in glucose-induced epithelial-to-mesenchymal transition in lung adenocarcinoma cells | |
Li et al. | Mechanisms of CXCR7 induction in malignant melanoma development | |
CN110317872A (zh) | 用于制备检测、预后和诊断乳腺癌产品的分子标记物及试剂盒 | |
CN1315871C (zh) | 一种肿瘤相关蛋白及其编码基因与应用 | |
Zhang et al. | Active legumain promotes invasion and migration of neuroblastoma by regulating epithelial-mesenchymal transition | |
Tang et al. | Diagnostic value and underlying mechanism of nasal nitric oxide in eosinophilic chronic rhinosinusitis with nasal polyps |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Guan Feng Inventor after: Kang Zhuang Inventor after: Zhang Junting Inventor after: Wang Liang Inventor before: Zhang Junting Inventor before: Guan Feng Inventor before: Wang Liang Inventor before: Kang Zhuang |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20210118 Address after: 100039 No.10 Tieyi Road, Yangfangdian, Haidian District, Beijing Applicant after: BEIJING SHIJITAN HOSPITAL, CMU Address before: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 6 Tiantan Xili, Chongwen District, Beijing 100038 Applicant before: BEIJING TIANTAN HOSPITAL, CAPITAL MEDICAL University |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220713 Address after: 119 South Fourth Ring Road West, Fengtai District, Beijing 100070 Patentee after: BEIJING TIANTAN HOSPITAL, CAPITAL MEDICAL University Address before: 100039 No.10 Tieyi Road, Yangfangdian, Haidian District, Beijing Patentee before: BEIJING SHIJITAN HOSPITAL, CMU |